Clinical trials: Advanced Ovarian Cancer
Neoplasms, Neoplasms, Ovarian
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
The purpose of this study is to support the qualification of a replacement manufacturing site for DOXIL/CAELYX (doxorubicin HCL).
- Conditions
- Neoplasms, Neoplasms, Ovarian, Neoplasms, Breast, Advanced or Refractory Solid Malignancies
- Trial name
- NCT01815294
- Testing
- DOXIL/CAELYX (doxorubicin) Treatment Sequence AB, DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
- Where
- 8 sites in United States, Belgium and 2 more
- Volunteers
- 54 people
- Sponsor
- Janssen Research & Development, LLC
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00070096
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liver Cancer, Pancreatic Cancer
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Liver Cancer, Pancreatic Cancer, Brain Tumor, Breast Cancer
- Trial name
- NCT02541370
- Testing
- anti-CD133-CAR vector-transduced T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Ovarian Cancer, Fallopian Tube Cancer
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
This study is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in PFS (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in combination with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00479817
- Testing
- AMG 386, Paclitaxel
- Volunteers
- 161 people
- Sponsor
- Amgen
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic, and potential clinical benefit of PF-07209960…
- Conditions
- Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04628780
- Testing
- PF-07209960
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Locally Advanced or Metastatic Solid Tumor
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid…
- Trial name
- NCT03601897
- Testing
- Rebastinib, Paclitaxel
- Where
- 14 sites in United States
- Volunteers
- 177 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
This is a prospective, randomized, controlled Phase II clinical study designed to evaluate the efficacy and safety of adding Aitua Combination Antibody (a PD-1/CTLA-4 bispecific antibody) to standard neoadjuvant chemotherapy for…
- Conditions
- High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07432594
- Testing
- Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5)
- Volunteers
- 82 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastrointestinal Neoplasms, Ovarian Neoplasms
Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
The purposes of this study are: 1. To assess the maximum tolerated dose of low-dose UART(Upper Abdominal Radiation Therapy ) or WART(Whole Abdominal Radiation Therapy) given in combination with standard fixed dose-rate…
- Trial name
- GCC0319 (NCT00390182)
- Testing
- Gemcitabine
- Where
- 2 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- University of Maryland, Baltimore
Advanced Solid Tumor
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091)…
- Trial name
- NCT05932862
- Testing
- XL309, Olaparib
- Where
- 16 sites in United States
- Volunteers
- 429 people
- Sponsor
- Exelixis
Fallopian Tube Cancer, Ovarian Cancer
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00748527
- Testing
- carboplatin, decitabine
- Where
- 11 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- Cancer Research UK
Solid Malignancies, Non-Hodgkin's Lymphoma
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
The purposes of this study are to determine: the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle the side effects of AQ4N when given on the above schedule how much AQ4N is in the…
- Trial name
- NCT00090727
- Testing
- AQ4N
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novacea
Cancer, Melanoma
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
First-in Human study evaluating the safety, tolerability and efficacy of ENB003 in combination with Pembrolizumab in solid tumors. The study is separated into two parts.
- Conditions
- Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer
- Trial name
- NCT04205227
- Testing
- ENB003, Pembrolizumab
- Where
- 5 sites in United States, Australia
- Volunteers
- 137 people
- Sponsor
- ENB Therapeutics, Inc
Ovarian Cancer
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
This is a multicenter, open-label study of safety and efficacy of Quisinostat in combination with Paclitaxel + Carboplatin chemotherapy in patients with metastatic or locally advanced epithelial ovarian cancer, primarily…
- Trial name
- NCT02948075
- Testing
- Quisinostat, Paclitaxel, Carboplatin
- Where
- 6 sites in Russia
- Volunteers
- 31 people
- Sponsor
- NewVac LLC
Malignant Solid Tumour, Breast Cancer
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an…
- Conditions
- Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon, GIST
- Trial name
- NCT01376505
- Testing
- HER-2 vaccine, Extension HER-2 vaccine trial at OBD
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Robert Wesolowski
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Ovarian Cancer
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
The purpose of this study is to determine whether the investigational drug catumaxomab delivered in the planned treatment schedule is a safe and effective treatment for women with advanced ovarian cancer who experience a complete…
- Trial name
- NCT00377429
- Testing
- catumaxomab
- Where
- 12 sites in United States
- Volunteers
- 47 people
- Sponsor
- Neovii Biotech
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination
This trial is a randomized, open-label Phase I-2 multi-center study designed to evaluate the effect of Carboplatin-Paclitaxel-Bevacizumab (in combination and maintenance) vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib (Rucaparib…
- Trial name
- MITO25 (NCT03462212)
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 7 sites in Italy
- Volunteers
- 290 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced Solid Tumor, HR+/HER2- Breast Cancer
Study of AVZO-021 in Patients With Advanced Solid Tumors
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
- Trial name
- NCT05867251
- Testing
- AVZO-021, Palbociclib, Fulvestrant
- Where
- 13 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Avenzo Therapeutics, Inc.